Literature DB >> 10536178

Mutation analysis of the Smad3 gene in human ovarian cancers.

D Wang1, T Kanuma, F Takama, H Mizumuma, Y Ibuki, N Wake, A Mogi, Y Shitara, K Hagiwara, S Takenoshita.   

Abstract

The Smad3 gene is a member of the Smad family, vertebrate homologues of Drosophila Mad, and its gene product is a cytoplasmic element in the transforming growth factor-beta (TGF-beta) signaling pathway. Mutations in TGF-beta receptors and their cytoplasmic elements of transduction signals commonly accompany various cancers. Using PCR-SSCP analysis we searched for the presence of Smad3 gene mutations in 36 human ovarian cancers, and found that 15 cases (41. 7%) had a polymorphism at codon 103. Because this mutation was not accompanied by amino acid replacement, the present results show that the mutations in the Smad3 gene are unlikely to be involved in human ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536178     DOI: 10.3892/ijo.15.5.949

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  4 in total

1.  Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.

Authors:  Meera Nanjundan; Kwai Wa Cheng; Fan Zhang; John Lahad; Wen-Lin Kuo; Rosemarie Schmandt; Karen Smith-McCune; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 6.603

2.  Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.

Authors:  Wanglong Qiu; Frank Schönleben; Xiaojun Li; Gloria H Su
Journal:  Cancer Lett       Date:  2006-02-14       Impact factor: 8.679

3.  Lewis Y regulates signaling molecules of the transforming growth factor β pathway in ovarian carcinoma-derived RMG-I cells.

Authors:  Fei-Fei Li; Juan-Juan Liu; Da-Wo Liu; Bei Lin; Ying-Ying Hao; Jian-Ping Cong; Lian-Cheng Zhu; Song Gao; Shu-Lan Zhang; Masao Iwamori
Journal:  Int J Oncol       Date:  2011-12-13       Impact factor: 5.650

Review 4.  Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

Authors:  M Kretzschmar
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.